I’m equally frustrated about the share price, and have certainly been critical over the years. (IMP761 languishing)
I do think it was an extraordinary year and have zero heartburn regarding performance shares. This small team has performed regarding clinical development, with recent TACTI-003 enrollment completion being the biggest. Eftilagimod alpha in NSCLC is showing incredible progress, and project Optimus 90mg in breast cancer is ahead of schedule. If this company is going to stop being invisible to the market, it will be because of these productive efforts. The TACTI-003 HNSCC card being flipped over soon could change everything.
Ann: Proposed issue of securities - IMM, page-3
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48648 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 13814 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |